BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Oxford Spinout Vaccitech Raises $168 Million in Series B Financing Round

  Infectious disease-focused Vaccitech, which partnered with AstraZeneca and Oxford University on the development and manufacturing of that company’s COVID-19 vaccine, raised $168 million in a Series B financing round.

  March 17, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Merck Enters Into New Collab to Advance Neurodegenerative Candidates With Amathus

  Amathus Therapeutics, a biopharmaceutical company working on small molecule modulators across diverse genetically defined diseases, has entered into a strategic collaboration with Merck to develop novel small molecule treatment candidates for neurodegenerative diseases.

  March 17, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Pharm Country

  Ocugen to Seek EUA for India-Developed COVID-19 Vaccine in the United States

  Pennsylvania-based Ocugen has struck a deal to sell 100 million doses of a COVID-19 vaccine India’s Bharat Biotech in the United States later this year.

  March 17, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  BioSpace Global Roundup: Antiverse Scores $2 Million to Advance AI Antibody Program

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  March 17, 2021

   · 

  7 min read

   · 

  Alex Keown
• 

  Policy

  AstraZeneca Troubles Continue as Study Shows Ineffectiveness Against South African Variant

  France and Germany are two out of more than a dozen countries that suspended deployment of the AstraZeneca-Oxford University vaccine after reports of blood clots were reported.

  March 17, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Business

  Valence/Repare Collab Capitalizes on AI to Optimize Precision Oncology Candidates

  In recent years, AI-fueled drug discovery programs have risen dramatically, particularly in regard to rare diseases.

  March 17, 2021

   · 

  3 min read

   · 

  Brandon May
• 

  Policy

  Former Biotech Director Charged with Obstruction of Justice Over Attempts to Acquire Neurotoxin Ricin

  The U.S. Attorney’s Office for Massachusetts charged Ishtiaq Ali Saaem, 37, with obstruction of justice for lying about his attempts to acquire 100 castor bean packets in order to develop the bioterror poison ricin. The acquisition was not recent, it took place on June 24, 2015.

  March 17, 2021

   · 

  2 min read

   · 

  Mark Terry
• 

  Deals

  FTC Joins Multinational Group to Crack Down on Biopharma Mergers

  The goal is to “identify concrete and actionable steps to review and update the analysis of pharmaceutical mergers.”

  March 17, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  FDA to Consider Allowing Trials for Algernon’s Psychedelic DMT

  Algernon Pharmaceuticals has requested a pre-Investigational New Drug meeting with regulators in the hopes of launching a clinical trial in stroke patients for n,n-dimethyltryptamine, a naturally derived psychedelic compound.

  March 17, 2021

   · 

  2 min read

   · 

  Mark Zipkin
• 

  Business

  Get to Know Sanjeev Luther, CEO and Board Member of Rafael Pharmaceuticals

  BioSpace recently spoke with Sanjeev Luther, CEO and board member of Rafael Pharmaceuticals, a clinical-late stage metabolic therapeutics company.

  March 17, 2021

   · 

  3 min read

   · 

  Gina Hagler